By Reuters
NYT World
The U.S. Food and Drug Administration approved Lundbeck A/S' migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday.
Published date: February 22, 2020 at 03:29AM
Reuters
New York Times article
No comments:
Post a Comment